Regulatory agencies, including the FDA and EMA, prefer terminal sterilization over aseptic manufacturing, as it is less complex, less costly, and easily reproducible―providing a higher level of sterility assurance and patient safety. Sterilization also takes place after formulation, once the product has been filled into the primary packaging, making it the optimal choice.

Learn more about our expertise and find out if terminal sterilization is suitable for your product.

Questions? Speak with one of our experts.

Related resources that may interest you:

Webinar: Advantages of Terminal Sterilization Over Aseptic Manufacturing                                                    
Scientific Journal: Terminal Sterilization of Pharmaceutical products

                             
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

Altasciences Ensures Nonhuman Primate Availability

Several preclinical CROs are expecting an impact on study start dates due to nonhuman primate (NHP) supply constraints. NOT Altasciences. We ensure NHP availability! We have the capacity at our four preclinical sites to start your studies six to eight weeks following contracting, thanks to our steady supply of NHPs.
 
SCHEDULE YOUR NHP STUDIES TODAY!

At Altasciences, we remove the stress of sourcing research animals so that you can start your studies when you need to, with:

•    dedicated and diversified cynomolgus monkey supply agreements in place to allow for faster start-up timelines;
•    a continuously maintained and backfilled population of hundreds of naïve NHPs at our preclinical facilities.

You can schedule newly contracted NHP studies to start immediately.

Have five minutes? Discover our extensive site capabilities:

Webpage: Full Range of Preclinical Drug Development Solutions
Fact Sheet: Preclinical Services Capabilities
The Altascientist: Planning Your Preclinical Assessment

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

At Altasciences, we specialize in diverse immunomodulators, including proteins, oligonucleotides, biologics, bispecific antibodies, and gene therapy.

Our evaluations count on essential biomarkers, like cytokines, complement factors, immune cell subtyping, and functional measurements.

Rely on us for:

• precise drug quantitation and biomarker assessment;
• state-of-the-art bioanalytical platforms to monitor multiple aspects of     immunomodulation in various species;
• bioanalytical teams with relevant experience handling pathogens and working with infectious samples for your vaccine development programs; and
• labs equipped with containment Level 2 (CL2) areas for handling pathogens within the Risk Group 2.

VIEW FACT SHEET

Need more guidance? Send us a message.

You may also be interested in the below resources: 

• eBook: Key Biomarkers of Immunomodulation: Complement Factors and Cytokines
• Webinar: Development of a Cell-Based Assay for Dual Purposes
• Webpage: Bioanalytical Platforms

Altasciences has been recognized as a 2023 CRO Leadership Award Champion in the Capabilities category, as voted by you in ISR’s annual CRO Quality Benchmarking survey.

Excellence in Ophthalmic Safety Testing

Altasciences has been conducting ophthalmic safety testing for decades, with all global regulatory submissions from our studies approved for design, conduct, and data integrity. We perform ocular pharmacokinetic studies in multiple species (rodent and non-rodent), using different types of formulations and routes of administration, and support study durations ranging from single-dose acute to studies of six and nine months.

Learn more about our early phase ophthalmic drug development expertise in our latest eBook.
 
VIEW EBOOK

Do you have an ocular drug compound in your development pipeline?
Speak with one of our experts about your study or end-to-end, preclinical to clinical proof-of-concept program. Let’s get you started!

Related resources that may interest you:

The Altascientist: The Complexities of Early Phase Ophthalmic Drug Development
Fact Sheet: Comprehensive Services for Ophthalmic Drug Development

​​​​​​